News from

CAR T Cell Therapy

Reset All Filters
23 Results
New CAR T treatment opens doors for kidney patients
Anatomy of two kidneys

Image: jitendrajadhav via Getty Images

New CAR T treatment opens doors for kidney patients

An early Penn Medicine trial demonstrates CAR T cells can safely desensitize even the most challenging transplant candidates.

Matt Toal

2 min. read

A retrospective on CAR T cell therapy: From long shot to lifesaver
(From left) Bruce Levine, Stephan Grupp, Tom Whitehead, Emily Whitehead, Kari Whitehead, Carl June, David Porter.

(From left) Bruce Levine, Stephan Grupp, Tom Whitehead, Emily Whitehead, Kari Whitehead, Carl June, and David Porter.

(Image: Daniel Burke)

A retrospective on CAR T cell therapy: From long shot to lifesaver

More than 30,000 patients have undergone CAR T cell therapy since it was developed by immunologist Carl June and his team at the University of Pennsylvania.

1 min. read

Targeting tumor supporting cells: Advancing CAR T success in pancreatic cancer
Pancreatic cancer cells.

Image: Nemes Laszlo/Science Photo Library via Getty Images

Targeting tumor supporting cells: Advancing CAR T success in pancreatic cancer

Research led by Penn Vet’s Ellen Puré has used lipid nanoparticles to generate CAR T cells directed at a type of tumor support cells—cancer-associated fibroblasts—melting away the protective barrier around pancreatic tumor cells and paving the way for a potentially safer, more accessible, and cost-effective method to treat solid tumors.

3 min. read

New CAR T strategy targets most common form of heart disease
a close-up view of a coronary artery with cholesterol plaque signifying cardiovascular disease and atherosclerosis

Kateryna Kon/Science Photo Library via Getty Images

New CAR T strategy targets most common form of heart disease

Preclinical research from investigators at Penn Medicine shows that experimental CAR T cells block inflammation in arteries, preventing more than two-thirds of the plaque buildup seen in untreated controls.

2 min. read

Tumor-on-a-chip offers insight into cancer-fighting cells in immunotherapy
Hand holding a microdevice

Penn engineers and collaborators have developed a transparent, micro-engineered device that houses a living, vascularized model of human lung cancer—a “tumor on a chip”—and show that the diabetes drug vildagliptin helps more CAR T cells break through the tumor’s defenses and attack it effectively.

(Image: Courtesy of Hiajiao Liu)

Tumor-on-a-chip offers insight into cancer-fighting cells in immunotherapy

Penn engineers and collaborators have built a living tumor on a chip to expose how cancers block immune attacks, and how one existing drug could make immunotherapy like CAR T more effective against solid tumors.

3 min. read